Gentium S.p.A. (GENT) announced that the medical team from the National University Corporation Hamamatsu University School of Medicine or HUSM, Fukushima Medical University or FMU have successfully administered defibrotide to the first subject in the phase 1 clinical study.
This Investigator led clinical trial aims "to evaluate the Safety and Pharmacokinetics of Defibrotide or DF in Healthy Adults."
The trial has been adopted as a Health and Labour Sciences Research Grant in 2012 for Practical Use of Medical Technology (categorized as a study project to support practical drug/medical device use during the reconstruction of disaster-hit areas in eastern Japan).
Gentium noted that it is providing defibrotide and technical support to HSUM.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.